KDCA “will monitor development of oral COVID-19 treatments"

By Lee, Hye-Kyung | translator Alice Kang

21.10.28 05:17:47

가나다라 0

On the criticism regarding the improvement of clinical symptoms, the authority will comprehensively review treatments with verified efficacy.

Interim analysis of the Phase III trial on molnupiravir showed that the drug reduced risk of hospitalization and death by 50%.

The government expressed its determination to introduce a safe treatment with verified efficacy by continuously monitoring the COVID-19 treatment trends, including the US Merck & Co. (MDS)'s oral COVID-19 treatment, 'molnupiravir .'

That was the KDCA's response to when NA member Young-seuk Seo of the Democratic Party of Korea asked in via a written inquiry about verifying the efficacy of molnupiravir after the NA audit that was held by the Health and Welfare Committee.

Seo asked,” The published results show patients who took placebo or molnupiravir until Day 5 and had no virus detection. Authorities need to consider whether a drug this potent is necessary to increase relief among the p

Lee, Hye-Kyung(hgrace7@dailypharm.com)

If you want to see the full article, please JOIN US (click)